Lykan opens manufacturing facility for cell therapies
Lykan Bioscience has opened a new, 64,000-sq-ft "smart" manufacturing facility in Hopkinton, MA.
Moderna, Vertex collaborate on gene editing therapies for cystic fibrosis
Moderna and Vertex Pharmaceuticals have entered a three-year research collaboration for the discovery and development of lipid nanoparticles and messenger RNAs for the delivery of gene editing therapies for the treatment of cystic fibrosis.
ERS Genomics inks licensing agreement with Applied StemCell
ERS Genomics said that it has signed a licensing agreement with Applied StemCell to commercialize CRISPR gene editing services and reagents.
Takeda opens new cell therapy manufacturing facility
Takeda Pharmaceuticals said it has opened a new 24,000-sq-ft research and development (R&D) cell therapy manufacturing facility at its R&D headquarters in Boston.
Bristol Myers Squibb licenses cell therapy candidate from Obsidian
Bristol Myers Squibb has exercised an option to an exclusive worldwide license to a cell therapy candidate based on Obsidian Therapeutics' cytoDrive technology.
Hexagon Bio secures $47M to advance drug discovery platform
Hexagon Bio has closed $47 million in series A financing to advance its drug discovery capabilities on its fungal genomics-based platform.
Sherlock launches nonprofit to promote equity, STEM during COVID-19
Sherlock Biosciences has formed the 221b Foundation, a nonprofit organization committed to assisting in the eradication of COVID-19, while supporting racial and gender diversity in STEM.
Optofluidics technology accelerates discovery of COVID-19 treatments
Known for its transformative technology, Berkeley Lights is a pioneer in optofluidics, which has supported the biopharmaceutical industry for years with its deep cell characterization capabilities. These efforts are highlighted by the rapid impact that Berkeley Lights' Beacon systems had during the early days of the COVID-19 pandemic.  Discuss
Neogene Therapeutics to develop personalized cell therapies
Neogene Therapeutics is pioneering a new class of fully personalized neoantigen T-cell therapies to treat cancer supported by $110 million in series A financing.
Neurocrine, Voyager tout gene therapy clinical results for Parkinson's disease
Neurocrine Biosciences and Voyager Therapeutics have released data from a phase Ib open-label, three-year efficacy and safety study of NBIb-1817, an investigational gene therapy to improve motor function in patients with Parkinson's disease.
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter